Department of Pediatric Endocrinology and Metabolic Diseases, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Search for other papers by Farzaneh Rohani in
Google Scholar
PubMed
Search for other papers by Mohammad Reza Alai in
Google Scholar
PubMed
Search for other papers by Sedighe Moradi in
Google Scholar
PubMed
Search for other papers by Davoud Amirkashani in
Google Scholar
PubMed
Poyrazoğlu et al . ( 8 ) indicate the final height (FH) of these children are short related to parental height. They should be treated before puberty to reach to the target height (TH) and predicted adult height (PAH). Soliman et al . ( 7 ) believed in
Search for other papers by Ping Li in
Google Scholar
PubMed
Search for other papers by Fei Cheng in
Google Scholar
PubMed
Search for other papers by Lei Xiu in
Google Scholar
PubMed
common feature of TS, untreated women are approximately 20–21 cm shorter than normal women within their respective populations ( 3 , 4 , 5 , 6 , 7 , 8 ). Recombinant human growth hormone (rhGH) has been shown to increase growth and final height in
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Mette Marie Baunsgaard in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Anne Sophie Lind Helligsoe in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Louise Tram Henriksen in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Torben Stamm Mikkelsen in
Google Scholar
PubMed
Search for other papers by Michael Callesen in
Google Scholar
PubMed
Search for other papers by Britta Weber in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Henrik Hasle in
Google Scholar
PubMed
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark
Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark
Search for other papers by Niels Birkebæk in
Google Scholar
PubMed
, GHD can be monitored by linear growth. However, assessment of linear growth is of no use when final height has been reached. Furthermore, insulin-like growth factor 1 (IGF-1) has been questioned as a reliable biochemical proxy marker of GHD in CR
Search for other papers by Urszula Smyczyńska in
Google Scholar
PubMed
Search for other papers by Joanna Smyczyńska in
Google Scholar
PubMed
Department of Paediatric Endocrinology, Medical University of Lodz, Lodz, Poland
Search for other papers by Maciej Hilczer in
Google Scholar
PubMed
Search for other papers by Renata Stawerska in
Google Scholar
PubMed
Search for other papers by Ryszard Tadeusiewicz in
Google Scholar
PubMed
Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
Search for other papers by Andrzej Lewiński in
Google Scholar
PubMed
-acquired GHD in 20042016 for at least one year (1st year response model), including 133 patients (89 boys, 44 girls) treated up to the attainment of FH (final height model). In both models, most of children were prepubertal at therapy onset; however, 1st
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Mojca Zerjav Tansek in
Google Scholar
PubMed
Search for other papers by Ana Bertoncel in
Google Scholar
PubMed
Search for other papers by Brina Sebez in
Google Scholar
PubMed
Search for other papers by Janez Zibert in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Urh Groselj in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Tadej Battelino in
Google Scholar
PubMed
University of Ljubljana, Faculty of Medicine, Ljubljana, Slovenia
Search for other papers by Magdalena Avbelj Stefanija in
Google Scholar
PubMed
difference in final height in cPKU compared to non-cPKU treated adult patients ( P = 0.012). Furthermore, the mean serum Phe and variability in serum Phe negatively predicted body height SDS (β = −0.562, P < 0.001; β = −0.262, P = 0.009) in the treated
Search for other papers by Patrizia Bruzzi in
Google Scholar
PubMed
Search for other papers by Silvia Vannelli in
Google Scholar
PubMed
Search for other papers by Emanuela Scarano in
Google Scholar
PubMed
Search for other papers by Natascia Di Iorgi in
Google Scholar
PubMed
Search for other papers by Maria Parpagnoli in
Google Scholar
PubMed
Search for other papers by MariaCarolina Salerno in
Google Scholar
PubMed
Search for other papers by Marco Pitea in
Google Scholar
PubMed
Search for other papers by Maria Elisabeth Street in
Google Scholar
PubMed
Search for other papers by Andrea Secco in
Google Scholar
PubMed
Search for other papers by Adolfo Andrea Trettene in
Google Scholar
PubMed
Search for other papers by Malgorzata Wasniewska in
Google Scholar
PubMed
Search for other papers by Nicola Corciulo in
Google Scholar
PubMed
Search for other papers by Gianluca Tornese in
Google Scholar
PubMed
Search for other papers by Maria Felicia Faienza in
Google Scholar
PubMed
Search for other papers by Maurizio Delvecchio in
Google Scholar
PubMed
Search for other papers by Simona Filomena Madeo in
Google Scholar
PubMed
Search for other papers by Lorenzo Iughetti in
Google Scholar
PubMed
paediatric endocrinologists at baseline, at the beginning of rhGH treatment (time 0 (T0)), yearly on rhGH therapy (T1, T2, T3 and T4) and at near-final height (nFH) (T5), when available, and were anonymously recorded in a database using an alphanumeric and
Search for other papers by M Ahmid in
Google Scholar
PubMed
Search for other papers by C G Perry in
Google Scholar
PubMed
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Search for other papers by M G Shaikh in
Google Scholar
PubMed
–IGF axis has important metabolic effects on a variety of target tissues ( Fig. 1 ). Historically, treatment with recombinant human GH (rhGH) was discontinued at final height as defined by a growth velocity less than 2cm/year ( 1 ). However, extensive
Search for other papers by Gudmundur Johannsson in
Google Scholar
PubMed
Search for other papers by Martin Bidlingmaier in
Google Scholar
PubMed
Search for other papers by Beverly M K Biller in
Google Scholar
PubMed
Search for other papers by Margaret Boguszewski in
Google Scholar
PubMed
Search for other papers by Felipe F Casanueva in
Google Scholar
PubMed
Search for other papers by Philippe Chanson in
Google Scholar
PubMed
Search for other papers by Peter E Clayton in
Google Scholar
PubMed
Search for other papers by Catherine S Choong in
Google Scholar
PubMed
Search for other papers by David Clemmons in
Google Scholar
PubMed
Search for other papers by Mehul Dattani in
Google Scholar
PubMed
Search for other papers by Jan Frystyk in
Google Scholar
PubMed
Search for other papers by Ken Ho in
Google Scholar
PubMed
Search for other papers by Andrew R Hoffman in
Google Scholar
PubMed
Search for other papers by Reiko Horikawa in
Google Scholar
PubMed
Search for other papers by Anders Juul in
Google Scholar
PubMed
Search for other papers by John J Kopchick in
Google Scholar
PubMed
Search for other papers by Xiaoping Luo in
Google Scholar
PubMed
Search for other papers by Sebastian Neggers in
Google Scholar
PubMed
Search for other papers by Irene Netchine in
Google Scholar
PubMed
Search for other papers by Daniel S Olsson in
Google Scholar
PubMed
Search for other papers by Sally Radovick in
Google Scholar
PubMed
Search for other papers by Ron Rosenfeld in
Google Scholar
PubMed
Search for other papers by Richard J Ross in
Google Scholar
PubMed
Search for other papers by Katharina Schilbach in
Google Scholar
PubMed
Search for other papers by Paulo Solberg in
Google Scholar
PubMed
Search for other papers by Christian Strasburger in
Google Scholar
PubMed
Search for other papers by Peter Trainer in
Google Scholar
PubMed
Search for other papers by Kevin C J Yuen in
Google Scholar
PubMed
Search for other papers by Kerstin Wickstrom in
Google Scholar
PubMed
Search for other papers by Jens O L Jorgensen in
Google Scholar
PubMed
Search for other papers by on behalf of the Growth Hormone Research Society in
Google Scholar
PubMed
is used as a biomarker for adherence. Its relationship to growth rate and final height is influenced by other variables including bone age, birth length and nutritional status, and it therefore has a limited role as a marker of efficacy. This is
Search for other papers by Monica F Stecchini in
Google Scholar
PubMed
Search for other papers by Zilda Braid in
Google Scholar
PubMed
Search for other papers by Candy B More in
Google Scholar
PubMed
Search for other papers by Davi C Aragon in
Google Scholar
PubMed
Search for other papers by Margaret Castro in
Google Scholar
PubMed
Search for other papers by Ayrton C Moreira in
Google Scholar
PubMed
Search for other papers by Sonir R Antonini in
Google Scholar
PubMed
with androgen-secreting ACTs may be at increased risk of developing early activation of the HPG axis, and that final height (FH) may not be impaired if adequate treatment is used. Therefore, the objective of this study was to investigate the impact of
Search for other papers by Thomas Reinehr in
Google Scholar
PubMed
Search for other papers by Martin Carlsson in
Google Scholar
PubMed
Search for other papers by Dionisios Chrysis in
Google Scholar
PubMed
Search for other papers by Cecilia Camacho-Hübner in
Google Scholar
PubMed
that both methods can be used in final height prediction considering the limitations reported in previous but also in the present study. New methods for bone age determination have been developed based on MRI, ultrasonography and computer-based analyses